TGFB1 and cancer: Alternatively, a gene editing approach may be considered, in which NK cells collected from a healthy donor are modified to no longer express p35, then injected into the cancer patient with the expectation that they display increased resistance to TGFβ-mediated dysfunction and heightened cytotoxic activity against the cancer cells.